Towards improved frontline treatment of CLL in the elderly
Mené dans 16 pays sur 447 patients atteints d'une leucémie lymphocytaire chronique (âge médian : 69 ans), cet essai randomisé évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout d'ofatumumab au chlorambucil
Chronic lymphocytic leukaemia is the most common leukaemia in western countries and mainly affects elderly people: the median age at diagnosis is 72 years. Nonetheless, elderly people have been under-represented in most landmark trials. Findings from such studies therefore had little validity for elderly patients with chronic lymphocytic leukaemia.
The Lancet , commentaire, 2014